The recombinant gene was not the underlying profitability of the company to save significant uncerta-clonecd

The recombinant gene was not the underlying profitability of the company to save significant uncertainty hot column capital flows thousands thousands of stocks the latest Rating Rating diagnosis simulated trading client sina finance App: Live on-line blogger to guide your entries you make you take will always let you falls in Beijing business news (reporter intern reporter Cui Qibin Gao Ping) Shennong gene (300189) yesterday evening announcement that the Commission received notice of China, after Chinese Commission mergers and acquisitions of listed companies audit committee yesterday held the 2016 sixty-eighth merger working meeting of the audit committee, rejected the matters of the company issued shares to buy assets. The reorganization committee said, "application materials show that the subject of the company’s future profitability has great uncertainty, is not conducive to improving the quality of assets of listed companies, improve the financial situation, and enhance sustainable profitability, does not comply with the" management measures "major asset restructuring of listed companies forty-third provisions". According to the initial transaction, the company intends to price 700 million yuan to buy 61.52% stake in Bo Lian gene. Service research and development provides gene technology gene Bo Lian hybrid rice and other crops, is currently in development and commercial application of third generation hybrid rice seed production techniques in rice field. The purpose of this transaction is to accelerate the "third generation hybrid breeding technology" development and commercialization process, while creating new profit growth point. At the same time, the company said, after the completion of the transaction, the equity ratio of Shennong gene in gene Bo lian to further enhance the education development will increase production technology support and input to the third generation of hybrid. However, the restructuring was not made, Shennong gene Yu on the third generation of hybrid seed production technology in the aspects of lost this thrust wave lotus gene. Enter Sina Financial shares] discussion

神农基因重组被否 标的公司盈利能力存重大不确定性 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经App:直播上线 博主一对一指导 你参赛你赚你拿 总能让你过把瘾   北京商报讯(记者 崔启斌 实习记者 高萍)神农基因(300189)昨日晚间发布公告称,收到中国证监会的通知,经过中国证监会上市公司并购重组审核委员会昨日召开的2016年第68次并购重组委工作会议审核,否决了公司发行股份购买资产的事项。   重组委表示,“申请材料显示,标的公司未来持续盈利能力具有重大不确定性,不利于提高上市公司资产质量、改善财务状况、增强持续盈利能力,不符合《上市公司重大资产重组管理办法》第四十三条规定”。   据最初的交易方案显示,公司拟以7亿元的价格购买波莲基因61.52%股权。波莲基因主要提供杂交水稻等农作物基因技术的研究与开发服务,当前正进行第三代杂交育制种技术在水稻领域的研发及商业化应用。此次交易的目的是希望加速“第三代杂交育制种技术”的研发与商业化进程,同时创造新的盈利增长点。   同时,公司表示,交易完成后,神农基因在波莲基因的股权比例进一步提升,将加大对第三代杂交育制种技术研发支持与投入。不过,此次重组被否,使得神农基因在研究第三代杂交育制种技术方面失去了波莲基因这一助推力。 进入【新浪财经股吧】讨论相关的主题文章:

« »

Comments closed.